MADIT Randomized Trial to Reduce Inappropriate Therapy ... - 1

ePAPER READ

DOWNLOAD ePAPER

static.cardiovasculairegeneeskunde.nl

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

MADIT-RIT: POPULATION• 1,500 pts. enrolled from 98 centersin US, Canada, Europe, Israel & Japan• Average follow-up = 1.4 years

Serelaxin, A Novel Treatment for Acute Heart Failure- The RELAX - 1

Medical Faculty of Ruperto Carola University Heidelberg

Hartfalen: epidemiologie, risicofactoren en toekomst

MADIT-RIT: POPULATION• 1,500 pts. enrolled from 98 centersin US, Canada, Europe, Israel & Japan• Average follow-up = 1.4 years

Baseline Demographic and ClinicalCharacteristics(no significant differences in 22 variables among the 3 Rx groups)VariableTherapy GroupA B CConventional High-rate Duration-delay>170bpm >200bpm >170bpm(n=514) (n=500) (n=486)Age, yrs 64 63 62Male, % 70 71 72Ischemic, % 53 54 52EF, % 26 26 26

Page 1 and 2: MADIT Randomized Trial to ReduceIna
Page 3 and 4: MADIT-RIT: BACKGROUND• ICD is hig
Page 5 and 6: MADIT-RIT: Three Treatment Arms*Ran
Page 7: MADIT-RIT: MADIT-RIT Prespecified P
Page 11 and 12: Figure 2.Cumulative Probability of
Page 13 and 14: Arrhythmias Triggering FirstInappro
Page 15 and 16: MADIT-RIT: CONCLUSIONSImproved ICD

MADIT Randomized Trial to Reduce Inappropriate Therapy ... - 1

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?